Protocols
13 protocol(s) meet the specified criteria
Disease Site: Cervix Uteri
Protocol No.TitleStatus
20120139 A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials Open
AMC-083Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies A Trial of the AIDS Malignancy Consortium (AMC)Open
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaOpen
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
GOG-0225Can Diet and Physical Activity Modulate Ovarian, fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?Open
GOG-0263Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic LyphadenectomyOpen
GOG3005-M13-694A Phase 3 Placebo-controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serious Epithelial Ovarian, Fallopian tube, or Primary Peritoneal Cancer (M13-694 Protocol)Open
LCCC1326Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients Open
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
UNCPM21607UNCPM 21607 - Safety and acceptability of a community-based screen-and-treat strategy of cervical cancer prevention in rural Lilongwe, Malawi Open
Z31602Z 31602 - Breast and Cervical Cancer Survivorship Among HIV-Positive Women in ZambiaOpen